Prescribers' compliance with Summary of Product Characteristics of dabigatran, rivaroxaban and apixaban - a European comparative drug utilization study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • PE, PV consortium H. Gardarsdottir

Despite a tremendous increase of direct oral anticoagulants (DOACs) prescriptions in recent years, only few data are available analysing prescribers' adherence to Summary of Product Characteristics (SmPC). We aimed to assess adherence to registered indications, contraindications, special warnings/precautions, and potential drug-drug interactions for three DOAC compounds (dabigatran, rivaroxaban, apixaban) in six databases of five European countries (The Netherlands, United Kingdom, Spain, Denmark, Germany). We included adult patients (≥18 years) initiating DOACs between 2008 and 2015. For several SmPC items, broad definitions were used due to ambiguous SmPC terms or lacking data in some databases. Within the study period, a DOAC was initiated in 407,576 patients (rivaroxaban: 240,985 (59.1%), dabigatran: 95,303 (23.4%), apixaban: 71,288 (17.5%)). In 2015, non-valvular atrial fibrillation was the most common indication (>60% in most databases). For the whole study period, a substantial variation between the databases was found regarding the proportion of patients with at least one contraindication (inter-database range [IDR]: 8.2%-55.7%), with at least one special warnings/precaution (IDR: 35.8%-75.2%), and with at least one potential drug-drug interaction (IDR: 22.4%-54.1%). In 2015, the most frequent contraindication was 'malignant neoplasm' (IDR: 0.7%-21.3%) whereas the most frequent special warnings/precaution was 'prescribing to the elderly' (≥75 years; IDR: 25.0%-66.4%). The most common single compound class interaction was 'concomitant use of non-steroidal anti-inflammatory drugs' (IDR: 3.0%-25.3%). Contraindications, special warnings/precautions, and potential drug-drug interaction were present in a relevant number of new DOAC users. Due to broad definitions used for some SmPC terms, overall proportions for contraindications are prone to overestimation. However, for unambiguous SmPC terms documented in the databases sufficiently, the respective estimates can be considered valid. Differences between databases might be related to 'true' differences in prescription behaviour, but could also be partially due to differences in database characteristics.

OriginalsprogEngelsk
BogserieBasic & Clinical Pharmacology & Toxicology
ISSN1742-7843
DOI
StatusE-pub ahead of print - 10 okt. 2020

Bibliografisk note

This article is protected by copyright. All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 198595877